A multilocus technique for risk evaluation of patients with neuroblastoma

Clinical Cancer Research

Volumn 17, Issue 4, 2011, Pages 792-804

  Ambros, Inge M ^a   Brunner, Bettina ^a   Aigner, Gerhard ^b   Bedwell, Clare ^d   Beiske, Klaus ^f   Bénard, Jean ^g   Bown, Nick ^d   Combaret, Valerie ^h   Couturier, Jerome ⁱ   Defferrari, Raffaella ^j   Gross, Nicole ^k   Jeison, Marta ^l   Lunec, John ^e   Marques, Barbara ^m   Martinsson, Tommy ⁿ   Mazzocco, Katia ^j   Noguera, Rosa ^o   Schleiermacher, Gudrun ⁱ   Speleman, Frank ^p   Stallings, Ray ^q,r   Tonini, Gian Paolo ^j   Tweddle, Deborah A ^e   Valent, Alexander ^g   Vicha, Ales ^s   Van Roy, Nadine ^p   Villamon, Eva ^o   Ziegler, Andrea ^a   Preuner, Sandra ^a   Drobics, Mario ^b   Ladenstein, Ruth ^a   Amann, Gabriele ^c   Schuit, Robert J L ^t   Pötschger, Ulrike ^a   Ambros, Peter F ^a   more..

^a ST ANNA CHILDREN S HOSPITAL   (Austria)

^b AIT AUSTRIAN INSTITUTE OF TECHNOLOGY   (Austria)

^c UNIVERSITY OF VIENNA   (Austria)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h CENTRE LÉON BÉRARD   (France)

ⁱ INSTITUT CURIE   (France)

^j UNIVERSITY OF GENOA   (Italy)

^k LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^l SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^m NATIONAL INSTITUTE OF HEALTH DR RICARDO JORGE   (Portugal)

ⁿ SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^o UNIVERSITY OF VALENCIA   (Spain)

^p GHENT UNIVERSITY HOSPITAL   (Belgium)

^q ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^r OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^s UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^t MRC HOLLAND   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER PATIENT; CHROMOSOME 11Q; CHROMOSOME 15Q; CHROMOSOME 16P; CHROMOSOME 16Q; CHROMOSOME 19Q; CHROMOSOME 1Q; CHROMOSOME 20Q; CHROMOSOME 21Q; CHROMOSOME 2P; CHROMOSOME 3Q; CHROMOSOME 4P; CHROMOSOME 4Q; CHROMOSOME 5P; CHROMOSOME 6P; CHROMOSOME 7P; CONTROLLED STUDY; DIAGNOSTIC KIT; GENE LOCUS; GENE SEQUENCE; HUMAN; HUMAN CELL; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NEUROBLASTOMA; NEUROBLASTOMA CELL; PRIORITY JOURNAL; RISK ASSESSMENT; TUMOR CELL;

COMPUTER GRAPHICS; GENE AMPLIFICATION; GENETIC LOCI; GENETIC MARKERS; HUMANS; LIMIT OF DETECTION; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; RISK ASSESSMENT;

EID: 79951836741     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0830     Document Type: Article

References (33)

1. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009;27:289-97.
2. Ambros PF, Ambros IM, Brodeur GM, Haber M, Khan J, Nakagawara A, et al. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer 2009;100:1471-82.
3. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-16. (Pubitemid 37328872)
4. Cohn SL, Tweddle DA. MYCN amplification remains prognostically strong 20 years after its "clinical debut". Eur J Cancer 2004;40:2639-42.
5. Look AT, Hayes FA, Shuster JJ, Douglass EC, Castleberry RP, Bowman LC, et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1991;9:581-91.
6. Ambros IM, Zellner A, Roald B, Amann G, Ladenstein R, Printz D, et al. Role of ploidy, chromosome 1p, and Schwann cells in the maturation of neuroblastoma [see comments]. N Engl J Med 1996;334:1505-11. (Pubitemid 26166893)
7. Maris JM, Weiss MJ, Guo C, Gerbing RB, Stram DO, White PS, et al. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study. J Clin Oncol 2000;18:1888-99. (Pubitemid 30261926)
8. Bown N, Cotterill S, Lastowska M, O'Neill S, Pearson AD, Plantaz D, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma [see comments]. N Engl J Med 1999;340:1954-61. (Pubitemid 29288271)
9. Schleiermacher G, Michon J, Huon I, d'Enghien CD, Klijanienko J, Brisse H, et al. Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification. Br J Cancer 2007;97:238-46. (Pubitemid 47057465)
10. Vandesompele J, Baudis M, De Preter K, Van Roy N, Ambros P, Bown N, et al. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J Clin Oncol 2005;23:2280-99. (Pubitemid 46218721)
11. Attiyeh EF, London WB, Mosse YP, Wang Q, Winter C, Khazi D, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005;353:2243-53. (Pubitemid 41697287)
12. Lastowska M, Viprey V, Santibanez-Koref M, Wappler I, Peters H, Cullinane C, et al. Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data. Oncogene 2007;26:7432-44. (Pubitemid 350158715)
13. Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin D, et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 2009;27:1026-33.
14. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 2002;30:e57.
15. Jeuken J, Cornelissen S, Boots-Sprenger S, Gijsen S, Wesseling P. Multiplex ligation-dependent probe amplification: a diagnostic tool for simultaneous identification of different genetic markers in glial tumors. J Mol Diagn 2006;8:433-43. (Pubitemid 44377925)
16. Cooke HJ, Hindley J. Cloning of human satellite III DNA: different components are on different chromosomes. Nucleic Acids Res 1979;6:3177-97. (Pubitemid 9238470)
17. Cohen J. A coefficient agreement for nominal scales. Psychol Meas 1960;20:37-46.
18. Fleiss JL. Measuring scale agreement among many raters. Psychol Bull 1971;76:378-82.
19. Bilke S, Chen QR, Whiteford CC, Khan J. Detection of low level genomic alterations by comparative genomic hybridization based on cDNA micro-arrays. Bioinformatics 2005;21:1138-45. (Pubitemid 40467938)
20. Selzer RR, Richmond TA, Pofahl NJ, Green RD, Eis PS, Nair P, et al. Analysis of chromosome breakpoints in neuroblastoma at sub-kilo-base resolution using fine-tiling oligonucleotide array CGH. Genes Chromosomes Cancer 2005;44:305-19. (Pubitemid 41397100)
21. Spitz R, Oberthuer A, Zapatka M, Brors B, Hero B, Ernestus K, et al. Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome. Genes Chromosomes Cancer 2006;45:1130-42. (Pubitemid 44763441)
22. Mosse YP, Diskin SJ, Wasserman N, Rinaldi K, Attiyeh EF, Cole K, et al. Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression. Genes Chromosomes Cancer 2007;46:936-49. (Pubitemid 47435023)
23. George RE, London WB, Cohn SL, Maris JM, Kretschmar C, Diller L, et al. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 2005;23:6466-73. (Pubitemid 46190237)
24. Michels E, Vandesompele J, De Preter K, Hoebeeck J, Vermeulen J, Schramm A, et al. ArrayCGH-based classification of neuroblastoma into genomic subgroups. Genes Chromosomes Cancer 2007;46:1098-108. (Pubitemid 47614544)
25. Tomioka N, Oba S, Ohira M, Misra A, Fridlyand J, Ishii S, et al. Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature. Oncogene 2008;27:441-9.
26. Ambros PF, Ambros IM, Kerbl R, Luegmayr A, Rumpler S, Ladenstein R, et al. Intratumoural heterogeneity of 1p deletions and MYCN amplification in neuroblastomas. Med Pediatr Oncol 2001;36:1-4.
27. Theissen J, Boensch M, Spitz R, Betts D, Stegmaier S, Christiansen H, et al. Heterogeneity of the MYCN oncogene in neuroblastoma. Clin Cancer Res 2009;15:2085-90.
28. Kerbl R, Urban CE, Ambros IM, Dornbusch HJ, Schwinger W, Lackner H, et al. Neuroblastoma mass screening in late infancy: insights into the biology of neuroblastic tumors. J Clin Oncol 2003;21:4228-34. (Pubitemid 46606193)
29. Villamon E, Piqueras M, Mackintosh C, Alonso J, de Alava E, Navarro S, et al. Comparison of different techniques for the detection of genetic risk-identifying chromosomal gains and losses in neuroblastoma. Virchows Arch 2008;453:47-55.
30. Elliot A, Baker A, Board J, Tweddle DA, Curtis A, Bown NP. MLPA analysis of neuroblastoma tumours. Chromosome Res 2007;15:165-6.
31. Ambros IM, Benard J, Boavida M, Bown N, Caron H, Combaret V, et al. Quality assessment of genetic markers used for therapy stratification. J Clin Oncol 2003;21:2077-84. (Pubitemid 46606355)
32. Weller M, Berger H, Hartmann C, Schramm J, Westphal M, Simon M, et al. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?Clin Cancer Res 2007;13:6933-7.
33. Shaffer LG, Tommerup N, editors. ISCN (2005): an international system for human cytogenetic nomenclature. Basel, Switzerland: S Kager; 2005.